Abstract
The paper reviews the literature on the use of methotrexate (MT) in rheumatoid arthritis (RA) and other rheumatic diseases. The efficacy and tolerability of MT are evaluated. The findings permit its consideration as the gold standard treatment for RA. The main adverse reactions of MT, which are given in the literature and have been observed by us for 28 years of its use in patients with RA, are described.
Highlights
Hospital Therapy Department One, Faculty of Therapeutics, I.M
The paper reviews the literature on the use of methotrexate (MT) in rheumatoid arthritis (RA) and other rheumatic diseases
The findings permit its consideration as the gold standard treatment for RA
Summary
В нашей клинике МТ для лечения больных РА, в том числе его ранних вариантов, используется с 1984 г., максимальная длительность непрерывной терапии составляет 28 лет (в среднем – 14,8 года). Применение МТ без назначения фолиевой кислоты в дозе 5 мг/нед через 24 ч после приема МТ недопустимо; 2) «идиосинкразические» или аллергические реакции (пневмонит), которые иногда купируются при прерывании лечения. Концентрация аминотрансфераз достигает максимума через 4–5 дней после приема препарата и сохраняется в течение 1–2 нед.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
